How the Tariffs Expose Vulnerabilities in the Pharma Pipeline
Arda Ural discusses the different ways that companies may change the ways they allocate resources in the current geopolitical climate.
Pharmaceutical Executive: What vulnerabilities do the current economic situation and tariffs expose for pharmaceuticals?
Arda Ural: If you look back over the past 30 years, through four recessions, we have not seen any economic impact on the pharmaceutical industry during those periods. The total number of prescriptions continued to increase during those years because people continued to get sick. This is not like retail or entertainment that feels an immediate toll.
CFOs have capital to allocate with a goal of maximizing shareholder return by virtue of return on invested capital. There’s competition for the source of capital that can be deployed. Companies can pay down their debts, increase their dividends, buy back shares, continue to invest in R&D, or they can put it into supply chain, ERP, and things like AI.
For that reason, that restriction may put pressure on the capital allocation practices of these companies. We advise our clients to make sure their return on invested capital still makes sense for shareholders and stake holders.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support
May 7th 2025Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
